Previous reports suggest that β-lap is a competent tumor-selective agent against many NQO1+ solid cancers, such as NSCLC, pancreatic and breast cancers (6, 11, 34–36), while the antitumor effect of this drug in liver cancer is still unknown. This evidence concerns the gene NQO1 and breast cancer.